Figure 2From: ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 DiabetesARA 290 (filled circles) administration exhibited a favorable increase in (A) the cholesterol/high density lipoprotein ratio (p = 0.039) and (B) high density lipoprotein (p = 0.066), as well as a decrease in (C) triglycerides (p = 0.043), in contrast to the placebo group (open circles).Back to article page